August 2026 retina highlights: Catch up on trial, regulatory, and diagnostic updates
A priority review in Stargardt disease, two pivotal-trial milestones, an emerging bispecific for wet AMD, and new diagnostic guidance defined a busy August for retina.
August 2026 was a pipeline-driven month for retina, with movement concentrated at the regulatory front and in late-phase trial operations. A priority review decision in an inherited retinal disease headlined the period, while 2 pivotal programs in diabetic macular edema (DME) and uveitic macular edema hit enrollment and cohort milestones that set up readouts through 2027. Alongside the pipeline news, clinicians got a pointed reminder that diagnostic precision still matters, particularly as invasive therapies reach the clinic. Catch up on any major news you may have missed below.